Typhoid Infection - Prevention is more Crucial than Treatment

Antibiotic resistant strains of S. typhi are increasing rapidly, including multi-drug resistant strains and those less sensitive to quinolones, such as ciprofloxacin. We are running out of treatment options, making vaccination against typhoid even more imperative.*

*Drs. F. VARGAS, W. MOLLER, A. ARBES - Annecy, France, Les Hospitaliers, April 2-6, 2007
Vi Capsular Polysaccharide Typhoid Vaccine

Typhoid fever continues to be a serious public health problem in many developing countries*

According to the World Health Organization (WHO), there are 16 million to 33 million cases & 500,000 to 600,000 deaths from typhoid fever annually.**

Efficacy and Safety of TYPBAR
Double-Blind & Randomized Clinical Study confirms:

- Proven Safety & Immunogenicity
- Demonstrated Efficacy
- Proven track record with usage in more than 50 countries

Comparison of Seroconversion of TYPBAR and Reference Vaccine

![Seroconversion Comparison Graph]

- No Animal Derived Growth Media, no BSE/TSE contaminants
- Least Reactogenic due to low endotoxin levels
- Also available as a Pre-Filled Syringe (ready to use injection)

Complications accompanying Typhoid infection
- Intestinal bleeding or perforation
- Myocarditis
- Pneumonia
- Pancreatitis
- Kidney or bladder infections
- Osteomyelitis
- Meningitis